19 March 2018 - Deborah Wilkes
Dr Reddy's has launched a generic version of Sanofi Consumer Healthcare's Xyzal Allergy 24HR (levocetirizine dihydrochloride) tablets in the US.
The Indian generics company said the "first-to-market launch" was a "testament to the deep capabilities of its store-brand OTC business".
Quoting data from IRI for the 52 weeks ending 28 January 2018, Dr Reddy's said the Xyzal Allergy 24HR tablets brand had US sales of approximately USD71 million.
Sanofi Consumer Healthcare launched Xyzal Allergy 24HR in the US in early 2017. The company markets oral tablets containing 5mg levocetirizine for children and adults aged six years and older, as well as a 0.5mg/ml oral solution for ages two years and older.
Read all about OTC/consumer healthcare strategies in the new OTC Company Strategies 2018 Report published by the OTCToolbox website on 14 March 2018.
– 270 pages
– Executive Summary of key global OTC/consumer healthcare trends
– 18 OTC/consumer healthcare Company Strategy Profiles
Click here to purchase and download